The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Combination of AbbVie's venetoclax and Rituxan succeeds in phase 3 R/R CLL trial.....           CMC Biologics signs development and manufacturing deal with Harpoon Therapeutics.....           NIH to provide funding for Alzheimer's advance clinical trials.....           Serum Institute eyes pharma's big-selling vaccines as CEO touts growth ambitions.....           Sanofi wins approval of Admelog with plans to snatch some of Humalog's blockbuster sales.....           ASH: Merck's Keytruda nabs speedy FDA review in non-Hodgkin lymphoma.....           Insider trading case against Ackman, Valeant approaches trial: report.....           Why are Shire's shares struggling? Some investors just don't understand, says CEO.....           Teva turnover continues with resignation of former chairman, interim chief.....           Sanofi?s Admelog (insulin lispro injection) gets FDA approval to treat diabetes.....           Ardelyx signs license agreement with Fosun Pharma for tenapanor in China.....           Aeonian Pharmaceuticals secures funding to develop mTORC1 inhibitors.....           ASH: AbbVie's Venclexta trounces chemo in Rituxan CLL combo study.....           Pfizer's breast cancer drug improves progression-free survival in Phase 3 trial.....           Teva's job-cut tally could touch 10K: report.....           ASH: J&J, AbbVie tout long-term Imbruvica data in the face of a new AstraZeneca threat.....           Sanofi official testifies to Dengvaxia's safety as questions in Philippines multiply.....           Roche touts more Tecentriq-plus-Avastin data, this time in kidney cancer.....           ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts.....           PhRMA files lawsuit as it takes another run at stopping California's controversial pricing law.....           ASH: Long-term CAR-T data look good for Gilead?but good enough to top its rivals?.....           ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half.....           Lilly?s Cyramza meets primary endpoint in phase 3 gastric cancer trial.....           Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant.....           NICE says lenvatinib should be available on NHS.....           Tax bill may target pharma's DTC deduction, but ad industry's ready to defend it.....           AstraZeneca taps Biggest Loser host Bob Harper for heart attack survivors push.....           Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst.....           FiercePharmaAsia?JLABS? Shanghai site, Sanofi?s Dengvaxia crisis, Astellas? $450M DMD buy.....           Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen?s blockbuster.....           Activists press Alexion for stepped-up guidance, boardroom edits: report.....           Gilead Sciences to acquire Cell Design Labs in $567m deal.....           bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy.....           Report expects global cryotherapy market to cross $4bn by 2024.....           Roche?s lung cancer drug combo study shows improvement in progression-free survival.....           Specialty pharmacy scrutiny hits again with state's focus on Horizon meds.....           Philippines plans legal action against Sanofi over Dengvaxia safety scare: official.....           Can Roche's Tecentriq leapfrog rival meds in lung cancer? Jury's still out.....           Pfizer's legendary Viagra finally set to face cheaper competition in U.S......           Novartis' Kisqali improves PFS in younger women with advanced breast cancer.....           Carmot, Amgen form drug discovery partnership.....           Fate Therapeutics, University of California San Diego launch CAR NK Cancer immunotherapy collaboration.....           GSK to invest £40m in UK's life sciences sector.....           Should pharma embrace the dark side? If that means dark social, definitely, agency says.....           Johnson & Johnson, Sanofi top 'Good Pharma' trial transparency ranking with perfect scores.....           In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst.....           Settle down, Allergan investors. Botox's market share is safe, analysts say.....           Clovis' Rubraca takes aim at Lynparza, Zejula with priority review for new use.....           In Supreme Court petition, Merck argues that FDA power shields against liability.....           NICE issues early 'no' votes on Roche's RoActemra, Novartis' Rydapt.....           Growth in retail drug spending freefalls along with hepatitis C drug costs, analysis says.....           Novo Nordisk?s Ozempic diabetic drug secures FDA approval.....           Realm Therapeutics doses first patient in phase 2 study of PR022 to treat atopic dermatitis.....           Arena, Everest Medicines partner for Ralinepag and Etrasimod in China.....           Janssen?s Imbruvica- rituximab combination meets primary end point in phase 3 study.....           Novo wins FDA blessing for Ozempic, a weekly diabetes drug carrying big expectations.....           J&J, Bayer lose first Xarelto bleeding case, hit with $28M verdict.....           Sanofi ordered to pull Dengvaxia in Philippines as safety episode escalates.....           As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report.....           Arizona asks for permission to manage Medicaid drug coverage.....           Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs.....           Novo wins FDA blessing for Ozempic, a weekly diabetes drug carrying big expectations.....           J&J, Bayer lose first Xarelto bleeding case, hit with $28M verdict.....           AbbVie?s risankizumab meets all primary endpoints in fourth phase 3 psoriasis trial.....           Blue Oak, PsychoGenics enter into drug discovery partnership.....           Researchers show aspirin added to cancer drug improves effectiveness.....           Social listening data is good, but it's better when combined with offline insights: agency.....           Sanofi's Dengvaxia scrutiny mounts as Philippines slams brakes on dengue shots.....           Pfizer tops Dow's intellectual heap, with J&J and Merck close behind: study.....           Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod.....           After a phase 3 flop, Sanofi cans its C. diff vaccine hopes.....           Bayer pulls veil back on Xofigo-Zytiga combo study after deaths, fractures crop up.....           Amgen gets its shot at promoting Repatha to prevent heart attacks and strokes.....           EMA investigates Allergan blockbuster hopeful Esmya on reports of liver damage.....           Amgen?s Repatha approved by FDA for heart attack and stroke prevention.....           I-Mab Biopharma partners with MorphoSys on cancer investigational medicine.....           Astellas Pharma acquires Mitobridge for $225m.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Forthcoming events

APS Developability Workshops 2018

The Academy of Pharmaceutical Sciences announce further workshops for their enormously popular Developability Workshop which ran in 2017

30 & 31 January 2018 - Alderley Park Conference Centre, Macclesfield, Cheshire
10 & 11 April 2018 - The Portway Building, Granta Park, Great Abington, Cambridge

You will learn from a pharmaceutics and biopharmaceutics perspective what is required to assess a molecule in discovery and its suitability for ‘candidate selection’; determine how ‘developable’ it is with associated risk, time and cost implications and what is needed to progress it through pre-clinical studies and into Phase 1 and 2a clinical studies to achieve Proof of Concept. The workshop will focus on the formulation and analytical aspects of early stage product development for small molecules for oral delivery in particular and put these activities into context with the other disciplines required to progress an asset.

The workshop will be interactive with real life examples, lectures and the ability of attendees to raise issues with compounds they are working on.

For more information and to register for either workshop, go here for Alderley Park, or here for Granta Park.

 
 
APS at FIP

Date: Friday 7 September 2018
Location: Hilton Hotel, Glasgow

The APS at FIP conference, will be held in Glasgow, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference which will take place in the city from the 2nd to the 6th September. The one day APS conference will have its usual focus on the pharmaceutical sciences with the theme and session have been selected to fit in with the two of the topics of the FIP conference:

  • From bench to bedside: Advancing pharmaceutical care
  • Targeting special interests

We are pleased to announce this year’s science chair is Dr Claire Thompson.

I am delighted to be the Science Chair of the 2018 conference which will be held in Glasgow on 7th Sep. The theme of the event is “The Science of Differentiated Medicines” and will include sessions on:

  • Age-related medicines
  • Medicines and diagnostics for the developing world
  • Targeted therapies
  • Medicines for specialised populations

The conference will delve into the science which underpins targeting therapies for cancer, formulations for paediatric and geriatric medicines, and the innovation required to develop and deliver healthcare solutions for the poorest countries in the world. I look forward to seeing you in Glasgow for what will be a fantastic event!

Claire is an award-winning scientist and innovator with more than 15 years’ experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual and Contract Research Organisations. She is the Founder of Agility Health Tech, a consulting and communications firm which works with organisations across the healthcare space to advance their products and raise their profile. She is also Deputy Chief Scientist of the Royal Pharmaceutical Society.

Having taken a range of therapeutic products through clinical Phases 1 to 3, she thrives on translating innovative technologies into healthcare products and shaping technical and organisational strategies. She was honoured with the Royal Pharmaceutical Society’s Pharmaceutical Science Award in 2015, and the Academy of Pharmaceutical Sciences’ Medal in 2016.

Before founding Agility Health Tech, she was Head of Research and Development with Oxford PharmaScience, an AIM-listed virtual Pharmaceutical company identified as one of the "Top 10 Emerging Technology Companies 2012". Here she evaluated and identified new technologies for in-licensing, transferring them from universities/companies and directed the scale-up through CROs/CMOs in adherence to EU and FDA cGMP requirements. She also engaged with investors, manufacturing and licensing partners to build capital, product supply and revenue respectively.

Prior to this, Claire was Associate Director at Molecular Profiles (now Juniper Pharmaceuticals) and spent 7½ years at GlaxoSmithKline and Pfizer developing novel molecules and formulations for therapeutic areas such as asthma, cancer, HIV, insomnia, malaria and pain.

Claire was Chief Scientist of the Academy of Pharmaceutical Sciences from 2012 -2016. She holds Honorary Senior Lectureships in the College of Medical & Dental Sciences at the University of Birmingham and the School of Pharmacy at University College London. She holds a PhD from School of Pharmacy, University of Nottingham, and a BSc in Biochemistry from the University of St. Andrews.

 
 

Reflections on APS PharmSci 2017 Conference

Date: 5 - 7 September 2017
Location: De Havilland Campus, University of Hertfordshire, Hatfield
Conference Chair: Professor Abdul Basit (University College London)
Theme: Pharmaceutical Science without Borders


A very successful 3-day conference provided an excellent interactive face to face forum for exchange of knowledge and sharing learnings and experiences in many aspects of the pharmaceutical sciences. With 80+ inspiring speakers and over 390 delegates joined together from academia, the Pharmaceutical Industry, and service companies. During the sessions, there was a steady flow of discussion which continued into the breaks and around the exhibition stands and posters.
 

Young pharmaceutical scientists had their first opportunity to present either a poster or podium presentation (or indeed both!) which is a major strength of APS PharmSci.

 

Read more, as Linda Hakes (Retiring APS Chair) and Mark McAllister (APS Chair) talk about their experiences at this year’s PharmSci.

Latest News
RPS Excellence in Pharmaceutical Science Excellence in Pharmaceutical Science Award
WEDNESDAY, 10 MAY 2017
Excellence in Pharmaceutical Science recognises those who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science. . The nominee should have demonstrated excellence in pharmaceutical science, by showing innovation and initiative, and contributing to a project which has had an impact on the improvement of pharmaceutical science.. To download the nomination form, please visit us online here:. https://www.rpharms.com/events/rps-awards. To be considered for the nomination the nominee must cover all aspects in the criteria. Completed nomination forms should be sent to events@rpharms.com by Monday 29 May 5pm..
Applications invited for the 2017 Royal Pharmaceutical Society Science Award
TUESDAY, 9 MAY 2017
Applications are invited for the 2017 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the Academy of Pharmaceutical Sciences International PharmSci Conference meeting on Thursday 7th September 2017.. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2017, applicants must have a proven record of independent research and published work that shows outstanding promise. . Applicants are invited to submit the following details by 31st May 2017: . · Full CV detailing personal information, past and present appointments, research responsibilities and published work. . · List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations . · Details of research grants awarded and the candidate’s role . · Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards . · A brief resume of two pages should also be submitted with the CV, indicating discoveries made (please note copies of publications are not required). . Submissions should be sent to: evidence@rpharms.com or by post to: Rachel Joynes, Head of Research Royal Pharmaceutical Society 66-68 East Smithfield London E1W 1AW. .
APS 8th International PharmSci Conference 2017 Call for Abstracts
THURSDAY, 12 JANUARY 2017
. 'Pharmaceutical Sciences Without Borders’. Tuesday 5 – Thursday 7 September 2017 De Havilland Campus of the University of Hertfordshire in Hatfield. Call for Abstracts. Abstracts are invited for posters for APS International PharmSci 2017. This is one of the most exciting parts of the conference as it represents the presentation of the very latest pharmaceutical science research.. Abstracts on any aspect of the Pharmaceutical Sciences are welcomed and those with a particular emphasis on the theme of this year’s Conference, 'Pharmaceutical Sciences Without Borders’ are particularly appreciated. Details of the various subject categories, an abstract template and details of the entry process can be found here:. http://www.ukpharmsci.org/abstracts/default.asp. Please ensure abstracts are submitted online and comply with the Abstract Submission Template. Please note one or two page abstracts are welcomed providing they follow the template.. There will be prizes awarded for winning posters on each day of the Conference and authors of abstracts of particular interest will be invited to give podium presentations (15min). This is an excellent chance to get your science recognised at the UK’s premier Pharmaceutical Science Conference. The closing date for abstract submission is Friday 17th March 2017.. Abstracts will be made available to Conference registrants when the abstract author has registered for the Conference. We also intend to publish the abstracts in a journal after the Conference and authors not wishing to take up this opportunity are requested to indicate this where indicated when they submit their abstract.. Entrants in the Analytical Chemistry category may be eligible for the Geoffrey Phillips Analytical Science Award, subject to meeting the criteria, awarded by the Joint Pharmaceutical Analysis Group (JPAG). The purpose of the Award is to encourage the advancement of pharmaceutical analysis and to recognise contributions of emerging scientists reporting wholly or mainly their own work. The winner receives a prestigious award with a bursary of up to £1000 to attend a conference relevant to their area of interest.. http://www.jpag.org/?&sid=20170112135948802597&p=awards#award. Exhibitor Opportunities. The conference includes a large pharmaceutical sciences exhibition, which is open to large pharma companies, small and medium size enterprises (SMEs), contract research organisations (CROs) and technology suppliers. With one of the largest gatherings of pharmaceutical scientists in the UK, the conference offers a great opportunity to showcase your company.. For more information please contact us: info@apsgb.org or 0116 274 7351. .
APS Fellowships Announcement 2017
WEDNESDAY, 2 NOVEMBER 2016
Do you know someone who has made a significant contribution to Pharmaceutical Science?. The APS is calling for nominations of candidates to become Fellow or Eminent Fellow of the Academy of Pharmaceutical Sciences.. Nominees for Fellowship must be a member of APS (for at least one year) and have a proven track record in pharmaceutical science, as demonstrated by at least 15 peer-reviewed publications, patents or equivalent. This would include significant contributions to the development of products or medical devises within the pharmaceutical industry. Nominees must also have demonstrated leadership and peer recognition through invited lectures, conference leadership, mentoring of young scientists etc. Candidates may self-nominate and nominations must consist of a one-page summary of achievements accompanies by a CV.. Nominations for Eminent Fellowship may be submitted by any member of APS but self-nominations are not accepted. Nominees for Eminent Fellowship must have international recognition for their advocacy of science and have demonstrated leadership at international level. Nominations should consist of a one-page summary of achievements and an explanation of why Eminent Fellowship is justified, and be accompanied by a CV.. Nominations should be sent to info@apsgb.org by 1 March 2017.

Follow us
 
Upcoming Events
APS Developability Workshop
30 - 31 January 2018
Emerging technologies in therapeutic oligonucleotides
13 March 2018
APS Current Regulatory trends and updates in parenteral drug product development
20 - 21 March 2018
APS Industrial Insights
26 - 27 March 2018
APS Developability Workshop
10 - 11 April 2018
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.